Chen Bihua's Form 4 filing
BridgeBio Oncology Therapeutics, Inc. (BBOT) · filed Feb 13, 2024
- Accession no.
- 0001213900-24-013534
- Filed
- Feb 13, 2024
- Trade date
- Feb 13, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $24.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chen BihuaCIK 0001599214 | Director, Officer (CEO and Chairperson), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | Class A Ordinary Shares | AGrant or awardAcquired | +509,000 | $10.00 | +$5,090,000 | 509,000 | Indirect | Duplicate filing |
| Feb 13, 2024 | Class A Ordinary Shares | PPurchaseAcquired | +69,360 | $10.00 | +$693,600 | 69,360 | Indirect | |
| Feb 13, 2024 | Class A Ordinary Shares | PPurchaseAcquired | +1,427,040 | $10.00 | +$14,270,400 | 1,427,040 | Indirect | |
| Feb 13, 2024 | Class A Ordinary Shares | PPurchaseAcquired | +903,600 | $10.00 | +$9,036,000 | 903,600 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.